And another meta-analysis of three large, population-based observational studies concluded that the risk of arterial and venous thromboembolism should be considered when evaluating the risk of thromboembolism attributed to ITP treatments (e.g. TPO-RAs)33. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.